Welcome to our dedicated page for Myriad Genetics SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Myriad Genetics, Inc. (NASDAQ: MYGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a molecular diagnostic testing and precision medicine company, Myriad Genetics uses these filings to report financial results, material agreements, leadership changes, and other significant events.
Investors can review Form 8-K filings that announce quarterly financial results, furnish earnings press releases, and describe items such as new credit agreements or changes in executive officers. For example, recent 8-K filings have covered results for quarters ended in 2025, entry into a term loan credit facility, and the appointment or departure of senior finance executives. An 8-K/A amendment has also been used to correct a clerical error in previously furnished financial information.
In addition to current reports, Myriad Genetics files annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, risk factor discussions, and segment information for areas such as hereditary cancer testing, tumor profiling, prenatal testing, and pharmacogenomics. Proxy statements and other governance-related documents provide further detail on board structure and executive compensation.
On Stock Titan, these filings are updated as they become available from the SEC’s EDGAR system. AI-powered tools summarize key points, highlight important sections, and help explain complex topics such as non-GAAP financial measures, credit facility covenants, and the implications of executive transitions. Users can also focus on insider and executive-related disclosures within Forms 3, 4, and 5 when those are filed, to better understand equity awards and ownership changes.
This page is intended as a convenient starting point for reviewing Myriad Genetics’ regulatory history and understanding how the company reports its financial condition, strategic agreements, and corporate governance matters over time.
Myriad Genetics reported an equity award to its Chief Financial Officer, Benjamin Richard Wheeler. On February 2, 2026, he acquired 4,994 shares of common stock at $0 per share, linked to previously granted performance-based restricted stock units (PSUs). These PSUs were originally granted on March 15, 2023, and the Compensation and Human Capital Committee set the final award amount based on performance metrics. Each PSU converts into one share of common stock and will vest on March 15, 2026. After this transaction, Wheeler beneficially owned 97,624 shares directly.
Myriad Genetics Chief Operating Officer Mark Verratti reported an award of common stock tied to earlier performance-based restricted stock units. On February 2, 2026, he acquired 32,810 shares of common stock at $0 per share, following certification of performance goals. After this award, he beneficially owned 414,636 shares directly. The underlying performance-based units were originally granted on March 15, 2023 and are scheduled to vest on March 15, 2026, with each unit representing one share of common stock.
Myriad Genetics reported that its Chief Scientific Officer, Dale Muzzey, received an award of 23,697 shares of common stock on February 2, 2026, at a price of
The shares relate to performance-based restricted stock units initially granted on March 15, 2023. The board’s Compensation and Human Capital Committee determined the final award amount based on pre-set performance metrics, and each unit will convert into one share of common stock vesting on March 15, 2026.
Myriad Genetics Chief Technology Officer Kevin Richard Haas reported an acquisition of 23,697 shares of common stock of the company on February 2, 2026 at a price of $0 per share. These shares relate to performance-based restricted stock units (PSUs) that were initially granted on March 15, 2023, with the final award amount determined by the board’s Compensation and Human Capital Committee based on preset performance metrics.
Each PSU represents a right to receive one share of Myriad Genetics common stock and is scheduled to vest on March 15, 2026. After this award, Haas beneficially owns 202,332 shares of Myriad Genetics common stock held directly.
Myriad Genetics Inc. has a new significant shareholder disclosure from Glenview Capital Management and its CEO Larry Robbins. As of January 12, 2026, they may be deemed to beneficially own 4,941,058 shares of Myriad Genetics common stock, representing approximately 5.3% of the shares outstanding.
The position is held across three Glenview-managed vehicles: 1,886,965 shares for Glenview Capital Master Fund, 2,791,657 shares for Glenview Offshore Opportunity Master Fund, and 262,436 shares for Glenview Healthcare Master Fund. Glenview and Robbins report shared voting and dispositive power over all 4,941,058 shares, with no sole voting or dispositive power. They also certify that the shares were not acquired to change or influence control of Myriad Genetics.
Myriad Genetics, Inc. reported preliminary operating trends for 2025 and introduced financial guidance for full year 2026. In a new press release, the company outlined early revenue figures for the quarter and year ended December 31, 2025 and shared its initial outlook for 2026.
For 2025, Myriad expects total test volumes of approximately 1.5 million, a 1% year-over-year increase. This reflects about 7% growth in hereditary cancer testing and 6% growth in mental health testing, partially offset by roughly a 4% decline in prenatal health testing. All financial figures are described as preliminary and remain subject to normal year-end accounting procedures and external audit, and the company includes standard cautionary language regarding forward-looking statements.
Myriad Genetics reported an insider equity event involving its President and CEO, Samraat S. Raha, who is also a director. On December 11, 2025, 29,634 shares of common stock were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, as indicated by transaction code F. The shares were valued using the closing price of Myriad common stock on that date, shown as
Myriad Genetics (MYGN)November 3, 2025, the reporting person no longer serves as EVP, Strategy & Transformation and therefore is no longer subject to Section 16 reporting.
The report lists 127,726 shares of common stock beneficially owned directly following the reported event. The form was filed by one reporting person.
Myriad Genetics reported Q3 2025 results showing steady operations but ongoing losses. Revenue was $205.7 million versus $213.3 million a year ago, with gross profit of $143.8 million and an operating loss of $23.3 million. Net loss for the quarter was $27.4 million, or $0.29 per share.
Segment trends were mixed: Hereditary Cancer revenue rose to $93.0 million, Prenatal to $44.5 million, while Pharmacogenomics fell to $38.7 million, reflecting lower average revenue per test and payer coverage changes. Year‑to‑date, the company recorded $316.7 million of goodwill and intangible impairments, driving a YTD net loss of $358.0 million and reducing intangible balances.
Liquidity strengthened with cash and equivalents of $145.4 million. Long‑term debt increased to $119.5 million after a new $125.0 million secured term loan maturing in 2030 at an interest rate of about 10.8%. The facility includes monthly trailing 12‑month revenue covenants beginning at $615.0 million as of December 31, 2025. Net cash used in operations was $8.8 million year‑to‑date.
Myriad Genetics (MYGN) filed an 8-K/A to correct a single figure in its recent earnings materials. The company revised the amount labeled “Cash, cash equivalents, and restricted cash at beginning of the period” for the three months ended September 30, 2025 to $83.7 million, replacing $101.0 million previously shown in the Condensed Consolidated Statements of Cash Flows included with its press release.
The company states this was a clerical error and that no other changes were made to the original 8-K or the press release. A corrected press release is furnished as Exhibit 99.1 and incorporated by reference.
FAQ
What is the current stock price of Myriad Genetics (MYGN)?
What is the market cap of Myriad Genetics (MYGN)?
